---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028759"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:12:02.965476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q3 net loss $0.10/share, cash $101.6M; advances OCU400 gene therapy and adds OCU500 mucosal vaccine

## Summary
- Net loss per share $0.10 vs $0.05 YoY; R&D $15.6M (up from $6.3M).
- Cash and equivalents $101.6M at Sep 30, 2022; provides runway into Q4 2023.
- COVAXIN Phase 2/3 enrollment completed; top-line data expected early 2023.
- OCU400 gene therapy: dosing began in Cohort 3 for retinitis pigmentosa; enrollment to complete by year-end; also to enroll LCA CEP290 patients.
- Expanded pipeline: OCU500 mucosal COVID-19 vaccine licensed from Washington University; OCU410ST for Stargardt disease.

## SEC filing metadata
- accession: 0001628280-22-028759
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/0001628280-22-028759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/ocgn-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028759
- JSON: https://secwatch.observer/filing/0001628280-22-028759.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028759.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported quarter ended September 30, 2022 results: net income $0.10 net loss per share, EPS $0.10 net loss per share.
  - Period: quarter ended September 30, 2022
  - Net income: $0.10 net loss per share
  - EPS: $0.10 net loss per share
  - Result: reported results
  source text: Ocugen reported a $0.10 net loss per share for the three months ended September 30, 2022, compared to a $0.05 net loss per share for the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/0001628280-22-028759-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.